一、基本信息
姓名：李玉华
职称：教授，主任医师
联系邮箱：liyuhua2011gz@163.com
二、学习经历
1991.9-1996.7 第一军医大学，临床医学专业，学士
1996.9-2001.7 第一军医大学，内科学（血液病）专业，博士
2005.5-2008.12 美国亚利桑那州立大学，博士后
三、拟招收博士后开展的研究方向
1. 肿瘤生物治疗：肿瘤疫苗治疗、CAR-T细胞治疗；
2. 难治性白血病耐药机制研究：TKIS耐药机制研究、白血病靶向药物研发；
3. 干细胞基因治疗和功能性研究：iPSCs技术研发、基因治疗单基因遗传病。
四、主要学术任职
1. 中国研究型医院学会血液病精准诊疗专业委员会常委
2. 中国人类遗传资源管理专家组成员
3. 中国抗癌协会第四届血液肿瘤专业委员会细胞治疗学组委员
4. 中国抗癌协会血液肿瘤专业委员会中国骨髓增生异常综合征和骨.髓增殖性肿瘤工作组专家委员会委员
5. 广东省女医师协会血液病学专业委员会主任委员
6. 广东省药学会第十七届理事会血液科用药专家委员会常委
7. 广东省医师协会血液科医师分会第二届委员会副主任委员
8. 广东省免疫学会临床免疫学专业委员会副主任委员
9. 国家自然科学基金评审专家
10. Journal of Hematology and Transfusion 审稿专家
11. International Journal of Stem cell Research & Therapy 审稿专家
五、主要获奖情况
1. 被评为“南粤巾帼好医师”，广东省女医师协会，2019；
2. 首批“广东省杰出青年医学人才”，广东省卫生健康委，2017；
3. 被评为“第一届珠江名师”，南方医科大学珠江医院，2017；
4. 被评为“南医优秀教师”，南方医科大学，2017；
5. 获“羊城好医生”称号，2016；
6. 荣获“教育部新世纪优秀人才”，国家教育部，2009；
7. 杀伤抑制信号在辐射伤后异基因骨髓移植中移植物抗宿主病的作用研究，中国人民解放军总后勤部，科技进步二等奖，2004。
六、代表性论文
1. Tu S, Huang R, Guo Z, Deng L,et al. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CRES or severe CRS. Am J Hematol. 2019 Sep 5.
2. Xiaoling Xie1, Yiran Chen, Yuxing Hu, et al. Lenalidomide augments the antitumor activities of Eps8 peptide-specific cytotoxic T lymphocytes against multiple myeloma. Mol Cancer Ther.2019 Aug 14 ;
3. Honghao Zhang, Lijuan Zhou, Weijun Zhou, et al. EPS8-mediated regulation of multiple myeloma cell growth and survival.Am J Cancer Res.2019 ;9(8):1622-1634.
4. Li M, Yang J, Zhang L, et al. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 2019.
5. Wu MR, Zhang LT, Zhang HZ, et al. CD19 Chimeric Antigen Receptor–Redirected T Cells Combined with Eps8 Peptide Derived Dendritic Cell Vaccine in Leukemia.Cytotherapy.2019 Jun ;21(6):659-67.
6. Xie X, Zhou W, Hu Y, et al. A dual-function epidermal growthfactor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potentcytotoxic T lymphocyte-activating effect and a specific inhibitory activity. CellDeath Dis. 2018 Mar 7;9(3):379.
7. Sun P, Zhou X, He Y, et al. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway. Biochem Biophys Res Commun. 2018 Mar 18; 497(4):990-996.
8. Chen Y, Xie X, Wu A, et al. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res 2018, 37:12.
9. Huang R, Liu H, Chen Y, et al. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Oncol Rep. 2018Jan;39(1):119-128.
10. Huang R, Hayashi Y, Yan X, et al. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 Nov;102(11):1956-1968.
11. Li D, Wang L, Hou J, et al .Optimized* Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder. Stem Cell Reports. 2016;10;6(5):717-728.
12. Huang R, Kang Q, Liu H,et al. New insights into the molecular resistance mechanisms of chronic myeloid leukemia. Curr Cancer Drug Targets. 2016; 16(4): 323-45.
13. Lan Deng, Ling Jiang, Kuo-Fu Tseng, et al. The increased expression of miR-146 predicts poor prognosis of immune thrombocytopenia. Int J Clin Exp Med 2016;9(6):9461-9466.
14. Tu S, Zhong D, Xie W, et al. Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases. Int J Mol Sci. 2016 Aug 11;17(8).
15.Tu S, Zhong D, Wu X, et al. Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder. Am J Med Sci. 2016 Oct;352(4):439-441.
16. Lu H, Tang B, He Y, et al. Identification of HLA A*1101 restricted cytotoxic T lymphocyte epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep. 2016 Dec;14(6):4999-5006.
17. Wei Chen, Jie Chen, Hongjiang Wei, et al. Association of hepatitis B virus basal core promoter T1762/A1764 and precore A1896 mutations with serum hepatitis B virus DNA load, hepatitis B e antigen status, serum α-fetoprotein and hepatitis B virus-related liver disease progression. Int J Clin Exp Med 2016;9(9):17309-17321.
18. Li Y, Zhou W, Du J, et al. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunol Immunother 2015; 64(2): 259-269.
19. Tang B, Zhou W, Du J, et al. Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep 2015; 12(2): 1741-1752.
20. He YZ, Liang Z, Wu MR, et al. Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia. Leuk Res 2015; 39(6): 575-581.
21. Chen Y, He Y, Lu X, et al. Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis. Int J Clin Exp Med. 2015 Mar 15;8(3):3817-3824.
22. Huang R, Tu S, Deng L, et al. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis. Hematology. 2015 Jul;20(6):313-319.
23. Deng L, Li MF, Li YH, et al.Chryseobacterium indologenes in four patients with leukemia. Transpl Infect Dis.2015 Aug;17(4):583-587.
24. Wang XJ, Li YH. Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate. Genet Mol Res. 2015; 11;14(2):6413-8.
25. Xu P, Li PJ, Guo K, et al. Remarkable Pathologic Change in Advanced Prostate Cancer PatientUsing Dendritic Cell-Cytokine-Induced Killer Combined Therapy: A Case Report.Clin Genitourin Cancer. 2015 Oct;13(5):e379-83.
26. Wang L, Cai SH, Xiong WY, et al. Real-time quantitative polymerase chain reaction assay for detecting the eps8 gene in acute myeloid leukemia. Clin Lab 2013; 59(11-12): 1261-1269.
27. Li YH, Xue TY, He YZ, et al. Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol 2013; 9(10): 1587-1594.
28. He YJ, Zhou J, Zhao TF, et al. Eps8 vaccine exerts prophylactic antitumor effects in a murine model: a novel vaccine for breast carcinoma. Mol Med Rep 2013; 8(2): 662-668.
29. Xue T, He Y, Zhang J, et al. KIR2DL1-HLA signaling pathway: notable inhibition in the cytotoxicity of allo-NK cell against KG1A cell. Clinical Laboratory. 2013; 59(5-6):613-619.
30. Hu L, Cao D, Li Y, et al. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer biology & therapy. 2012;13(7): 516-526.
31. Wang S, Li Y, Shi H, et al. Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines. Infect Immun. 2011;79(2): 937-949.
32. Huang Y, Wang Y, Li Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol. 2011; 137(5): 829-837.
33. Curtiss R, Xin W, Li Y, et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol. 2010;30(3): 255-270.
34. Wang S, Li Y, Scarpellini G, et al. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity. Infect Immun 2010; 78(9): 3969-3980.
35. Wang S, Li Y, Shi H, et al. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun. 78(7): 3258-3271.
36. Li C, Li Y, Zhang X, et al. ICRPfinder: a fast pattern design algorithm for coding sequences and its application in finding potential restriction enzyme recognition sites. BMC Bioinformatic. 2009;10:286.
37. Xin W, Li Y, Mo H, et al. PspA Family Fusion Proteins Delivered by Attenuated Salmonella enterica Serovar Typhimurium Extend and Enhance Protection against Streptococcus pneumoniae. Infect Immun. 2009; 77(10): 4518-4528.
38. Li Y, Wang S, Scarpellini G, et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 2009; 106(2):593-598.
39. Li Y, Wang S, Xin W, et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun 2008; 76(11):5238-5246.
40. Xin W, Wanda SY, Li Y, et al. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun. 2008; 76(7): 3241-3254.
41. Yuhua L, Kunyuan G, Hui C, et al. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer. 2001 Nov 1;94(3):438-43.
